In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Synthetic biology company Intrexon completes $150mm Series F round

Executive Summary

In the same month in which it has signed infectious disease deals with AmpliPhi Biosciences and Soligenix, Intrexon Corp. (multigenic technologies that regulate biological molecules used in human drugs, protein production, industrial applications, agriculture biotech, and animal health) has also completed a $150mm Series F offering of preferred stock to 57 investors. Most of the funding came from first-time backers, which were joined by affiliates of Intrexon’s chairman and CEO Randal J. Kirk and Third Security. Including the current round of financing, Intrexon has raised a total of $509mm since inception. The company will use the new money to forge additional collaborations in the health care, food, energy, and environmental areas; further develop its platforms; and expand its sales and marketing and R&D teams.
Deal Industry
  • Research, Analytical Equipment & Supplies
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Synthesis Technologies, Production Processes
    • Transgenics
    • Drug Discovery Tools
      • Genomics-Proteomics
      • Molecular Diversity
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies